Human IFN-beta Antibody

Catalog #: MAB814R Datasheet / COA / SDS

Recombinant Monoclonal Antibody

Catalog #	Availability	Size / Price	Qty
MAB814R-100
MAB814R-SP
MAB814R-500
MAB814R-01M

IFN-beta Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN-beta Antibody.

1 Image

All IFN-beta Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human IFN-beta Antibody Summary

Species Reactivity

Human

Specificity

Detects human IFN‑ beta in direct ELISAs.

Source

Recombinant Monoclonal Mouse IgG₁ Clone # 76703R

Purification

Protein A or G purified from cell culture supernatant

Immunogen

E. coli-derived recombinant human IFN‑ beta
Met22-Asn187
Accession # P01574

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

Measured by its ability to neutralize IFN-beta inhibition of EMCV-inducedcytopathy in the HeLa human cervicalepithelial carcinoma cell line. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens,M.J. et al. (eds): IRL Press. 129. The Neutralization Dose (ND₅₀) is typically 1.50-18.0μg/mL in the presence of50 pg/mL Recombinant Human IFN-beta.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

IFN-beta Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN-beta Antibody. Recombinant Human IFN-beta (Catalog # 8499-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-beta (50 pg/mL) is neutralized (green line) by increasing concentrations of Recombinant Human IFN-beta Monoclonal Antibody (Catalog # MAB814R). The ND₅₀ is typically 1.50-18.0 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-beta

Interferon beta (IFN-beta ) is synthesized and secreted by fibroblasts and many other cell types in response to pathogens. IFN-beta binding to type I interferon receptors induces the upregulation of IRF-7 and activation of Rnase L. IRF-7 can exert a positive feedback on IFN-beta production. RNase L cleaves both viral and cellular single stranded mRNA, thereby limiting viral replication and dissemination.

Long Name

Interferon beta

Entrez Gene IDs

3456 (Human); 15977 (Mouse); 24481 (Rat)

Alternate Names

Fibroblast interferon; IFB; IFBIFNB; IFF; IFNB; IFNB1; IFNbeta; IFN-beta; interferon beta; interferon, beta 1, fibroblast; MGC96956